{"id":2169,"date":"2017-06-14T17:49:53","date_gmt":"2017-06-14T12:19:53","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2169"},"modified":"2021-10-12T11:13:28","modified_gmt":"2021-10-12T05:43:28","slug":"the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients","title":{"rendered":"New cancer drug tested in mice may benefit certain leukaemia patients"},"content":{"rendered":"<p style=\"text-align: justify;\">Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States. Up to 30 percent of adult acute lymphoblastic leukemia or ALL patients have Philadelphia chromosome, where two segments of chromosomes have aberrantly fused together. Adult ALL patients often see high relapse rates, and treatment-related deaths remain high. Researchers now report on a study that could provide better therapeutic options for patients. In the <em>Leukemia<\/em> study, HCI scientists learned how to inhibit and override the negative activity of this chromosome. The findings could possibly lead to future novel drug treatments. The Philadelphia chromosome promotes repair through numerous proteins. But putting together a cocktail of drugs to inhibit them all would likely be too toxic and affect normal cells. So, Srividya Bhaskara, HCI investigator and assistant professor of radiation oncology at the University of Utah, focused on two specific proteins she found directly involved in DNA repair, called histone deacetylases (HDAC) 1 and 2. She has now collaborated with a company to make a drug that inhibits HDAC1,2 activity. The HDAC1,2 inhibitor drug has been tested in patient samples and mice, showing encouraging results, either alone or in combination with a chemotherapy drug called doxorubicin.<\/p>\n<p style=\"text-align: justify;\">To read more, click <a href=\"https:\/\/www.sciencedaily.com\/releases\/2017\/06\/170609193059.htm\">cancer drug trial<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States. Up to 30 percent of adult acute lymphoblastic leukemia or ALL patients have Philadelphia chromosome, where two segments of chromosomes have aberrantly fused together. Adult ALL patients often see high relapse rates, and treatment-related [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2170,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[137,927,928,699,930,929],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-2169","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-cancer","tag-cancer-treatment","tag-hdac-inhibitor","tag-leukemia","tag-oncology-research","tag-university-of-utah","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mice tested caner drug brings hope to leukaemia patients<\/title>\n<meta name=\"description\" content=\"Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mice tested caner drug brings hope to leukaemia patients\" \/>\n<meta property=\"og:description\" content=\"Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-06-14T12:19:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-12T05:43:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/06\/09021259\/1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"456\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mice tested caner drug brings hope to leukaemia patients","description":"Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients","og_locale":"en_US","og_type":"article","og_title":"Mice tested caner drug brings hope to leukaemia patients","og_description":"Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States.","og_url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-06-14T12:19:53+00:00","article_modified_time":"2021-10-12T05:43:28+00:00","og_image":[{"width":600,"height":456,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/06\/09021259\/1.jpeg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients","url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients","name":"Mice tested caner drug brings hope to leukaemia patients","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/06\/09021259\/1.jpeg","datePublished":"2017-06-14T12:19:53+00:00","dateModified":"2021-10-12T05:43:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-new-cancer-drug-tested-in-mice-may-benefit-certain-leukemia-patients#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/06\/09021259\/1.jpeg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/06\/09021259\/1.jpeg","width":600,"height":456},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/06\/09021259\/1-300x228.jpeg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">HDAC inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Oncology Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">University of Utah<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">HDAC inhibitor<\/span>","<span class=\"advgb-post-tax-term\">leukemia<\/span>","<span class=\"advgb-post-tax-term\">Oncology Research<\/span>","<span class=\"advgb-post-tax-term\">University of Utah<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jun 14, 2017","modified":"Updated on Oct 12, 2021"},"absolute_dates_time":{"created":"Posted on Jun 14, 2017 5:49 pm","modified":"Updated on Oct 12, 2021 11:13 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2169"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2169\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2170"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2169"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2169"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}